Sign in
4

Changes in Ownership

Definium Therapeutics, Inc. Filed Acc 0001104659-26-112061

Chief Commercial Officer sold 3,097 shares at $36.57 ($113,257)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Wiley Matthew T. Chief Commercial Officer 2026-09-25 Sale 10b5-1 −3,097 $36.57 $113,257 359,036 D
Open-market sales · 3,097 sh · avg $36.57 · $113,257
Loading xslF345X06/tm2626627-3_4seq1.xml…